Most material SEC filings — August 25, 2026

Two Harbors Investment Corp. (NYSE: TWO), a $1.1B market-cap MSR-focused REIT, completed its merger with CrossCountry Mortgage LLC on August 25, 2026. TWO shareholders received $12.00 per share in cash plus a stub-period dividend of $0.20326 per share. TWO is now a private subsidiary of CCM and delisted from NYSE.

BEST SPAC I Acquisition Corp. (market cap ~$55.2M) received a delisting notice on 2026-08-19 for failure to satisfy continued listing rules or standards. The 8-K filing dated 2026-08-25 reports Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard). Specific reasons, remediation plans, or timeline details are not disclosed in the filing summary provided.

AstroNova shareholders voted to approve acquisition by Arcline Investment Management at $29.00 per share in cash. More than 99% of votes cast (representing ~64% of outstanding shares) approved the merger dated June 16, 2026. Transaction expected to close August 26, 2026, converting AstroNova to a private company with delisting from Nasdaq.

On August 21, 2026, Aimei Health Technology Co., Ltd. received notice of delisting or failure to satisfy continued listing rules/standards on Nasdaq, triggering Item 3.01 disclosure. No specific reason, remediation plan, or timeline details are provided in this 8-K filing. The filing contains only regulatory boilerplate and XBRL exhibits; no financial statements, dollar amounts, or operational details are disclosed.

Datavault AI Inc. filed an 8-K on August 25, 2026, disclosing a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has failed to meet exchange listing requirements. No specific remediation plan, timeline, or detailed reasons are provided in the filing text presented.

Olin Corporation (NYSE: OLN) and Huntsman Corporation (NYSE: HUN) announced shareholder approval of their previously announced all-stock merger on August 25, 2026. Olin shareholders voted 97% in favor (81% of outstanding shares), and Huntsman shareholders voted 99% in favor (75% of outstanding shares). The combined company, OlinHuntsman Corporation, is expected to close in first half 2027, subject to regulatory approvals and customary closing conditions.

On August 21, 2026, BioRestorative Therapies, Inc. received notice of delisting or failure to satisfy continued listing rules/standards (Item 3.01). The filing provides no specific details on which listing standard was breached, the timeline for remediation, or which exchange issued the notice. This represents a critical corporate governance event for the $11.2M market-cap company.

Quartzsea Acquisition Corp filed an 8-K on 2026-08-25 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The specific reasons, counterparties, dollar amounts, or remediation steps are not disclosed in the available filing header and XBRL metadata provided. The full substantive text of the 8-K filing is not included in this submission.

Barinthus Biotherapeutics plc is combining with Clywedog Therapeutics in an all-stock merger with a Scheme Exchange Ratio of 0.111 shares of Topco common stock per Barinthus share. Barinthus ADSs will cease trading on Nasdaq prior to market open September 3, 2026, with the combined entity listing as Clywedog Therapeutics Holdings, Inc. under ticker CLYD. The UK High Court hearing is scheduled for September 1, 2026, with scheme effectiveness expected September 3, 2026.

Olin Corporation (NYSE: OLN, $2.3B market cap) and Huntsman Corporation (NYSE: HUN, ~$6B revenue) shareholders voted to approve an all-stock merger of equals on August 25, 2026. Olin shareholders approved with 97% of votes cast (81% of shares outstanding); Huntsman shareholders approved with 99% of votes cast (75% of shares outstanding). The combined entity, OlinHuntsman Corporation, is expected to close in H1 2027 subject to regulatory approvals and customary closing conditions.

BioXcel Therapeutics executed the Fourteenth Amendment to its credit agreement dated August 24, 2026, adding a $1,250,000 Amendment No. 14 Term Loan from existing lenders (primarily Oaktree Capital funds and Qatar Investment Authority affiliate). Total facility increases from $202.3M to $203.6M. Key condition: borrower must execute definitive agreements for a transaction by August 31, 2026 that either pays debt in full or represents an acceptable alternative capital solution. Upfront fee is 20% of the new tranche commitment.

Between June 23 and August 19, 2026, an undisclosed insider purchased approximately 123,372 common shares of Phunware at prices ranging from $1.89 to $2.50. Concurrently, the insider shorted ~1,758 put option contracts (primarily Oct 2026 and Jan 2027 $2.50 strikes) while closing ~4,841 call contracts. Total stock purchases approximate $260K–$280K at current valuations. The filing does not identify the counterparties or disclose whether this represents a single investor or multiple parties. The net effect suggests aggressive accumulation coupled with income generation via short puts.

On August 20, 2026, Nasdaq notified Maison Solutions Inc. that it failed to timely file its Annual Report on Form 10-K for fiscal year ended April 30, 2026, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 calendar days (until October 19, 2026) to submit a compliance plan; if accepted, it receives a grace period until February 9, 2027 to file the 10-K. The stock remains listed on Nasdaq Capital Market under symbol MSS pending plan submission and acceptance.

On October 31, 2025, PEDEVCO closed its acquisition of North Peak Oil Gas (NPOG and COG), which owns ~281,000 net acres in Northern DJ and Powder River Basins with oil-weighted producing assets. Total consideration was approximately $179.9M: 10,650,000 Series A Convertible Preferred Shares (fair value $64.2M at $6.03/share) plus $115.7M cash to settle North Peak debt. Concurrently, investors purchased 6,363,637 PIPE Preferred Shares at $5.50/share for $35M, which converted to 3,181,818 common shares on February 27, 2026. Pro forma combined operations for 2025 show $132.2M revenue and $81K net loss.

reAlpha completed its InstaMortgage acquisition without obtaining required state regulatory approvals in two states that collectively represented 23.41% of InstaMortgage's 2025 loan origination volume (1.93% and 22.59% respectively) and 21.31% in H1 2026. The company faces potential material fines, penalties, business restrictions, or forced cessation of operations in these states pending approval. No timeline for resolution is provided.

Caring Brands Inc. issued up to 11,000 shares of Series B Convertible Preferred Stock (stated value $1,000/share) for up to $11,000,000 aggregate purchase price, effective August 21, 2026. Purchasers also received two separate warrants: Common Stock Purchase Warrant A (exercise price $0.825, 5-year term) and Common Stock Purchase Warrant B (exercise price $0.95, 5-year term), each to purchase up to shares equal to 100% of conversion shares. Series B carries 8% annual dividend and full-ratchet anti-dilution protection. Series A Preferred Stock (4,500 shares) was concurrently amended and restated with conversion price $0.40 and similar dividend/anti-dilution rights.

J.J. Astor Co., a counterparty under an Inventory Finance Agreement (originated May 27, 2025, amended November 3, 2025, and April 1, 2026), exercised conversion rights on August 17 and August 19, 2026. On August 17, Astor converted $75,608.38 of outstanding payment obligations into 30,290 shares at $2.49615/share. On August 19, Astor converted $92,357.55 into 37,000 shares at the same price. Combined: $167,965.93 converted to 67,290 shares. This represents debt-to-equity conversion under an existing financing arrangement.

Soluna subsidiary entered into a co-mining agreement with Dory Creek LLC (Bitdeer subsidiary) on August 25, 2026. Bitdeer will deploy approximately 28 MW of Bitcoin mining equipment (1.93 EH/s hash rate) at Soluna's Project Kati 1 in Texas, with deployment beginning September 2026. Under the co-mining structure, Soluna provides site/power/operations while Bitdeer owns the equipment; the parties share mining proceeds.

On July 16, 2026, Sadot Group Inc. (market cap ~$620M) entered into a $100M convertible note facility (initial $4M tranche closed, $1M second tranche pending) and a $100M equity purchase facility with SZOP Opportunities I LLC and ATW Sapphire LLC. This S-1/A registers 4.25M shares (292% of current outstanding) for resale by investors, including up to 2.5M shares from the equity line at market-driven prices and 1.75M conversion shares at a floor of $2.85/share. The company faces going-concern doubt, negative $5.9M shareholders' equity as of June 30, 2026, $13.6M working capital deficit, and $0.1M cash. Nasdaq compliance is conditioned on Q3 2026 results. Proceeds go to working capital; no proceeds from resales of investor shares.

Jazz Pharmaceuticals received FDA approval for Ziihera (zanidatamab) in first-line HER2+ gastroesophageal adenocarcinoma, both with and without tislelizumab plus chemotherapy. Zymeworks receives a $250M milestone payment from Jazz (total upfront+milestones: $650M) and remains eligible for up to $1.3B additional milestones plus 10–20% tiered royalties. This is zanidatamab's second FDA approval in less than two years; separately, BeOne collaboration has yielded $81M to date with up to $144M additional milestones plus up to 19.5% royalties.

For Q2 FY2026 ended August 1, 2026, Cato reported net income of $1.1M ($0.06/diluted share), down 84% from $6.8M ($0.35/share) in Q2 FY2025. Sales declined 6% to $163.9M from $174.7M; same-store sales fell 3.7%. Gross margin compressed to 32.8% from 36.2% due to lower merchandise margins and occupancy cost deleveraging. Store count fell to 1,057 from 1,101 year-over-year; 8 stores closed in Q2. Management cited persistent pressure on customer discretionary income from inflation, fuel prices, and elevated interest rates, expecting continued weakness in H2 2026.

Cecilia Lenk resigned as Director of Netcapital, Inc., effective immediately as of August 19, 2026 (corrected August 25, 2026). The resignation resulted from SEC v. Fanning, et al., Civil Action No. 26-13665 (D. Mass.), filed August 10, 2026, in which Lenk consented to a Final Judgment permanently enjoining her from participating in the issuance, purchase, offer, or sale of any security except for her own account. No dollar amounts, share counts, or other specific financial impacts are disclosed in this filing.

QumulusAI reported Q2 2026 revenue of $6.7M (118% YoY growth) with gross margin expanding to 67%. The company deployed 3,088 GPUs (224% increase), signed 21 new customer contracts valued at $169.7M, and achieved $282.5M cumulative signed contract value. Recent highlights include Nasdaq listing (July 16, 2026), NVIDIA Cloud Partner status, $120M+ new agreements including a $71M three-year contract, and a 3.75 MW Atlanta colocation agreement with expansion rights to 7 MW.

Effective June 30, 2026, Zachary C. Parker ceased employment as CEO and President of DLH Holdings Corp. Parker transitioned to advisory services (July 1–Sept 30, 2026) for $187,550 cash, then to consulting (Oct 1, 2026–Sept 30, 2027) for 142,857 RSUs (~$750k at $5.25/share) plus 19,047 PSUs (~$100k). Parker remains a non-employee board member receiving standard director compensation. The separation includes broad release of claims and continued confidentiality/non-compete obligations.

Fund 1 Investments, LLC purchased 2,931,458 shares of Xponential Fitness common stock between June 24 and August 21, 2026, at prices ranging from $4.88 to $7.12 per share, spending approximately $17.4M. The fund made three small sales totaling 592,000 shares for approximately $3.6M, yielding a net acquisition of roughly 2.34M shares, representing approximately 3-4% of estimated outstanding equity. This constitutes a reportable 5%+ threshold disclosure trigger under Schedule 13D.

Momentus Inc. filed an 8-K on 2026-08-25 reporting termination of a material definitive agreement effective 2026-08-21. The filing provides no details on the counterparty, dollar amounts, contractual terms, or reason for termination—only that Item 1.02 was triggered, indicating the agreement was deemed material to the company.

The CYPRESS Phase 3 trial of ampreloxetine for neurogenic orthostatic hypotension failed its primary endpoint—change in OHSA composite score at week 8 (randomized withdrawal period) was not statistically significant. Post hoc analyses of a refined 'confirmed symptomatic nOH' subpopulation (n=47) showed numerical improvements (p=0.001 for average OHSA, OHDAS, OHQ over weeks 2–8), but the pivotal trial did not succeed as designed. FDA indicated in May 2026 Type B meeting that approval is not supported by current data; however, the agency indicated an additional pivotal trial could offer a path forward. Theravance held a Type C meeting in July 2026 to discuss future study design.

Citi Trends reported Q2 FY2026 total sales of $211.6M (up 10.9% YoY) and comparable store sales growth of 10.5%, with net income of $6.8M for the first half vs. $4.7M in H1 FY2025. The company raised FY2026 guidance: comparable store sales growth now 9–11% (prior 8–10%), total sales 10–12% (prior 9–11%), and adjusted EBITDA $38–42M (prior $35–40M). The company ended Q2 with 594 stores, $55.9M cash, zero debt, and reduced new store guidance from 25 to 20 for the year.

Dick's reported Q2 diluted EPS of $3.50 (vs. $4.71 prior year) on net sales of $5.59B (vs. $3.65B), reflecting the September 2025 Foot Locker acquisition ($2.5B total consideration: $2.1B stock, $223M cash). Dick's core business delivered 4.9% comparable sales growth, but Foot Locker proforma comps declined 3.6% due to weak athletic footwear marketplace. Company lowered full-year 2026 Foot Locker proforma comp sales guidance to negative 2.0% to 0.0% (from prior outlook) and reduced operating income guidance for both segments; Dick's comp sales guidance maintained at 2.5%–4.0%.

Director Gorzynski Michael (AMR) bought 10K shares (~$2.1M) on the open market (1.5% of holdings). Open-market insider purchase — historically a bullish signal.

Semtech reported Q2 FY2027 net sales of $341.9M (up 17% sequentially, 33% year-over-year), with GAAP gross margin 53.8% and non-GAAP adjusted gross margin 54.5%. GAAP diluted EPS was $1.59; non-GAAP adjusted diluted EPS was $0.71. The company issued Q3 guidance of $410M net sales (±$5M), non-GAAP adjusted operating margin 31.0% (±60 bps), and adjusted diluted EPS $1.05 (±$0.03). Strong bookings and record backlog signal continued growth momentum into next fiscal year.

On August 25, 2026, the FDA approved Ziihera (zanidatamab-hrii) in two regimens for first-line treatment of HER2+ advanced gastroesophageal adenocarcinoma (GEA): with tislelizumab plus chemotherapy (for IHC 3+ and IHC 2+/ISH+) and with chemotherapy alone (for IHC 3+). The Phase 3 HERIZON-GEA-01 trial demonstrated median overall survival of 26.4 months versus 19.2 months with trastuzumab (28% reduction in death risk), and median PFS of 12.4 months versus 8.1 months (35% reduction in progression/death risk), establishing a new standard of care. Safety profile includes diarrhea in 79–85% of patients (Grade 3–4 in 24–36%), with 1.5–2.4% fatal outcomes and 10–13% permanent discontinuations.

Director Courtis Kenneth S. (AMR) bought 5K shares (~$1.1M) on the open market (0.5% of holdings). Open-market insider purchase — historically a bullish signal.

On June 2, 2026, Haoxin Holdings (a $50.3M-asset Chinese logistics company) entered two financing agreements with Mermaid Money LLC: (1) issued $1.2M face value convertible notes ($1M purchase price, 4% OID) convertible at 90% of 5-day VWAP floor, and (2) an Equity Line of Credit for up to $30M in Class A shares at market prices (Rapid or VWAP basis). Commitment: 2.75M shares granted; Warrant: 2.37M shares at $0.456/sh exercisable for 2 years. If all securities convert/exercise, Mermaid Money would own 66.8% of outstanding shares, creating massive dilution. Company is registered to resale 18M shares; actual issuance under ELOC discretionary, capped by trading volume and beneficial ownership limits (4.99%–9.99%).

10% owner PAINE SCHWARTZ FOOD CHAIN FUND V GP, LTD. (SUJA) bought 657K shares (~$5.7M) on the open market (5.9% of holdings). Open-market insider purchase — historically a bullish signal.

President and CEO Roks Edwin (TTMI) bought 10K shares (~$1.1M) on the open market (13% of holdings). Open-market insider purchase — historically a bullish signal.

Consumer Portfolio Services reported strong Q2 2026 results with auto contract purchases of $757.7M (75% increase vs. $433.0M in Q2 2025), managed portfolio reaching $4.43B (largest in company history), and net income of $6.2M ($0.27 diluted EPS) vs. $4.8M ($0.20 EPS) prior year. Shareholder equity reached $319.2M (highest on record), core operating expenses improved to 4.6% of portfolio (from 4.8%), and delinquencies declined to 12.16% (from 13.14%). Company maintains 59 consecutive profitable quarters with pretax ROA of 0.9% (up from 0.8% YoY).

Manitowoc updated 2026 full-year guidance: net sales raised to $2.3–$2.4B (prior $2.25–$2.35B); adjusted EBITDA raised to $150–$170M including $16M tariff refunds (prior $125–$150M); adjusted DEPS raised to $0.80–$1.20 (prior $0.45–$0.90). Company targets aspirational $3.0B+ revenue, $1.0B+ non-new machine sales, 12%+ adjusted EBITDA margin, and 15%+ adjusted ROIC by 5-year horizon. Non-new machine sales grew 84% from 2020–2025; backlog increased 44% YOY to $1.05B as of June 30, 2026.

Vyome (market cap ~$6.4M) reported Q2 2026 cash of $7.9M (vs. $5.0M at Dec 31, 2025), stockholders' equity of $7.3M, and Q2 net loss of $720K ($0.10/share). The company advanced lead program VT-1953 with Phase 2 data showing statistically significant improvements in malodor and lesion pain; received FDA written response to March 2026 pre-IND briefing and plans Type C meeting. Signed in-license agreement with Impetis Biosciences for two JAK inhibitor assets targeting autoimmune/inflammatory conditions. Company maintains zero debt and no toxic financing.